Centocor's mAb, by targeting a different pathway involved in the disease, represents an alternative line of therapeutic attack. Brian Kenney, Centocor's spokesperson, says Stelara delivers ...

New drug applications under the 505(b)(2) pathway are pending FDA approval, targeting conditions like migraines, hypertension, and CKD. Biosimilars, particularly in the ustekinumab space ...

Clinical Validation of the Role of the IL-23/Th17 Pathway in Psoriasis The validation of this pathway has, in large part been a result of the successful use of specifically targeted biologic ...

This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab ...

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg. The decision follows evidence ...